Combined analysis of COX-2 and p53 expressions reveals synergistic inverse correlations with microsatellite instability and CpG island methylator phenotype in colorectal cancer

被引:79
作者
Ogino, Shuji
Brahmandam, Mohan
Kawasaki, Takako
Kirkner, Gregory J.
Loda, Massimo
Fuchs, Charles S.
机构
[1] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA
[2] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
[3] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA
来源
NEOPLASIA | 2006年 / 8卷 / 06期
关键词
colon cancer; cyclooxygenase-2; DNA methylation; MethyLight; TP53;
D O I
10.1593/neo.06247
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Cyclooxygenase-2 (COX-2) overexpression and mutations of p53 (a known COX-2 regulator) are inversely associated with microsatellite instability-high (MSI-H) and CpG island methylator phenotype ( CIMP), characterized by extensive promotermethylation, is associated with MSI-H. However, no studies have comprehensively examined interrelations between COX-2, p53, MSI, and CIMP. Using MethyLight, we measured DNA methylation in five CIMP-specific gene promoters [CACNA1G, CDKN2A (p16/INK4A), CRABP1, MLH1, and NEUROG1] in relatively unbiased samples of 751 colorectal cancer cases obtained from two large prospective cohorts; 115 (15%) tumors were CIMP-high (>= 4 of 5 methylated promoters), 251 (33%) were CIMP-low ( 1 to 3 methylated promoters), and the remaining 385 (51%) were CIMP-0 ( no methylated promoters). CIMP-high tumors were much less frequent in COX-2+/p53+ tumors (4.6%) than in COX-2(+)/p53(-) tumors (19%; P <.0001), COX-2(-)/p53(+) tumors (17%; P =.04), andCOX-2(-)/p53(-) tumors (28%; P <.0001). In addition, COX-2(+)/p53(+) tumors were significantly less common in MSI-H CIMP-high tumors (9.7%) than in non-MSI-H CIMP-low/CIMP-0 tumors (44-47%; P <.0001). In conclusion, COX-2 and p53 alterations were synergistically inversely correlated with both MSI-H and CIMP-high. Our data suggest that a combined analysis of COX-2 and p53 may be more useful for the molecular classification of colorectal cancer than either COX-2 or p53 analysis alone.
引用
收藏
页码:458 / 464
页数:7
相关论文
共 48 条
[1]
Colorectal cancer "Methylator phenotype": Fact or artifact?' [J].
Anacleto, C ;
Leopoldino, AM ;
Rossi, B ;
Soares, FA ;
Lopes, A ;
Rocha, JCC ;
Caballero, O ;
Camargo, AA ;
Simpson, AJG ;
Pena, SDJ .
NEOPLASIA, 2005, 7 (04) :331-335
[2]
COX-2: A molecular target for colorectal cancer prevention [J].
Brown, JR ;
DuBois, RN .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (12) :2840-2855
[3]
Validation of tissue microarray technology in breast carcinoma [J].
Camp, RL ;
Charette, LA ;
Rimm, DL .
LABORATORY INVESTIGATION, 2000, 80 (12) :1943-1949
[4]
CpG island methylation in aberrant crypt foci of the colorectum [J].
Chan, AOO ;
Broaddus, RR ;
Houlihan, PS ;
Issa, JPJ ;
Hamilton, SR ;
Rashid, A .
AMERICAN JOURNAL OF PATHOLOGY, 2002, 160 (05) :1823-1830
[5]
The Nurses' Health Study: Lifestyle and health among women [J].
Colditz, GA ;
Hankinson, SE .
NATURE REVIEWS CANCER, 2005, 5 (05) :388-396
[6]
P53 alterations in colon tumors - A comparison of SSCP/sequencing and immunohistochemistry [J].
Curtin, K ;
Slattery, ML ;
Holubkov, R ;
Edwards, S ;
Holden, JA ;
Samowitz, WS .
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2004, 12 (04) :380-386
[7]
Cyclooxygenase-2 and epidermal growth factor receptor: Pharmacologic targets for chemoprevention [J].
Dannenberg, AJ ;
Lippman, SM ;
Mann, JR ;
Subbaramaiah, K ;
DuBois, RN .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (02) :254-266
[8]
Eads CA, 1999, CANCER RES, V59, P2302
[9]
MethyLight: a high-throughput assay to measure DNA methylation [J].
Eads, Cindy A. ;
Danenberg, Kathleen D. ;
Kawakami, Kazuyuki ;
Saltz, Leonard B. ;
Blake, Corey ;
Shibata, Darryl ;
Danenberg, Peter V. ;
Laird, Peter W. .
NUCLEIC ACIDS RESEARCH, 2000, 28 (08) :32
[10]
Hypermethylation of the TPEF/HPP1 gene in primary and metastatic colorectal cancers [J].
Ebert, MPA ;
Mooney, SH ;
Tonnes-Priddy, L ;
Lograsso, J ;
Hoffmann, J ;
Chen, J ;
Röcken, C ;
Schulz, HU ;
Malfertheiner, P ;
Lofton-Day, C .
NEOPLASIA, 2005, 7 (08) :771-778